Stocktoria
CytoDyn Inc. CYDY
OTC · OOTC · stock · Pharmaceutical Preparations · website · IPO 2005-11-17
CytoDyn Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $266,000 | $0 | — | — | — | — | — |
| Gross profit | — | — | — | $213,000 | — | — | — | — | — | — |
| R&D expense | — | $7.2M | $2.6M | $27.0M | $53.4M | $52.6M | $42.5M | $38.2M | $20.2M | $13.7M |
| Operating income | $9.7M | -$18.1M | -$40.6M | -$145.4M | -$104.6M | -$74.6M | -$55.9M | -$45.9M | -$27.3M | -$21.2M |
| Interest expense | — | — | — | — | — | $18.2M | $3.3M | $5.9M | $612,767 | $4.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | -$2.8M | $0 | $0 | $0 |
| Net income | $3.7M | -$49.8M | -$79.8M | -$210.8M | -$176.5M | -$139.9M | -$60.7M | -$50.1M | -$25.8M | -$25.7M |
| EPS (diluted) | $0.00 | $-0.05 | $-0.10 | $-0.31 | $-0.30 | $-0.33 | $-0.23 | — | — | — |
| Operating cash flow | -$8.8M | -$11.0M | -$25.1M | -$77.7M | -$117.6M | -$68.8M | -$50.5M | -$29.9M | -$26.7M | -$24.8M |
| Free cash flow | — | — | — | — | -$117.7M | -$68.8M | -$50.5M | -$29.9M | -$26.7M | -$24.8M |
| Cash & equivalents | $11.9M | $3.1M | $2.5M | $4.2M | $33.9M | $14.3M | $2.6M | $1.2M | $1.8M | $9.6M |
| Inventory | — | $0 | $0 | — | $93.5M | $19.1M | — | — | — | — |
| Total assets | $18.0M | $11.1M | $11.3M | $29.2M | $132.1M | $50.5M | $20.9M | $4.9M | $8.1M | $13.8M |
| Total liabilities | $114.1M | $127.9M | $120.8M | $123.6M | $153.1M | $53.0M | $29.8M | $18.1M | $9.2M | $3.6M |
| Shareholders' equity | -$96.0M | -$116.8M | -$109.5M | -$94.4M | -$21.0M | -$2.5M | -$8.9M | -$13.2M | -$1.1M | $10.2M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -100.0% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001175680 · as of 2025-05-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.